Infectious Disease

Infectious Disease

Infectious diseases kill nearly 10 million people a year; primarily in developing countries, where access to preventive care and treatment is limited. But even in the United States, new strains of disease emerge periodically, which must be addressed quickly and effectively.

Key Initiatives

Grand Challenges in Global Health

Funded by the Gates Foundation, Grand Challenges in Global Health encompasses 43 project across 33 countries, working toward scientific breakthroughs to prevent, treat, and cure diseases that kill millions each year.

Key Initiatives

MAL-ED: A Global Network for the Study of Malnutrition and Enteric Diseases

Poor nutrition is linked to more than half of all child deaths worldwide. This initiative, funded by the Gates Foundation, draws together an international group of scientific investigators to study the inter-relationship between enteric infections and malnutrition to reduce its devastating effects.

Key Initiatives

CTC-VIMC: Supporting the Development of a Vaccine for HIV/AIDS

The Foundation for NIH is one of 19 consortia comprising the Collaboration for AIDS Vaccine Discovery. Funded by the Gates Foundation, this initiative is aimed toward developing an effective AIDS vaccine.

Program

HIT-TB: Identification of High-quality HITs for Tuberculosis

The new HIT_TB project is another Foundation and the National Institute of Allergy and Infectious Diseases, along with Pfizer Inc., and academic institutions in the United Kingdom and South Africa. Its focus is on combating tuberculosis, which infects one-third of the world’s population.

Program

Vector-based Control of Transmission: Discovery Research (VCTR)

VCTR logoThe “Vector-based Control of Transmission: Discovery Research” program is an extension of the Grand Challenges in Global Health initiative, aimed at establishing a pipeline of innovative new tools that will be safe, easily deployed, effective and sustainable for u

Program

Centralized Envelope Comparative Immunogenicity Study (CECI)

This project aims to address a fundamental problem blocking the development of a successful HIV-1 vaccine. The goal is to understand how best to design T cell immunogens to address the broad genetic diversity of HIV-1.